⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRIX News
Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
globenewswire.com
NRIX
Nurix Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
NRIX
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
globenewswire.com
NRIX
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
globenewswire.com
NRIX
Form 8-K
sec.gov
NRIX
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
globenewswire.com
NRIX
Nurix Therapeutics to Participate in Upcoming Investor Conference
globenewswire.com
NRIX
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
globenewswire.com
NRIX
Form 8-K
sec.gov
NRIX
Molecular Glues Competitive Landscape Research Report 2026: Comprehensive Insights About 80+ Companies and 90+ Drugs
globenewswire.com
BMY
RVMD
NRIX